Call to Schedule Free Consultation at Over 80 Centers Worldwide!

(844) GET-STEM

Can MUSE Stem Cells Help Repair Heart Disease and Myocardial Infarction?

Written by Dr. David Greene, MD, PhD, MBA on September 1, 2026

Table of Contents

Ischemic heart disease and acute myocardial infarction (heart attack) remain leading causes of morbidity and mortality worldwide. When a blockage restricts blood supply to the myocardium, oxygen deprivation causes cardiomyocytes (heart muscle cells) to die, leaving behind non-contractile scar tissue. Because the human heart has limited natural regenerative capacity, damaged tissue often leads to progressive heart failure, characterized by reduced ejection fraction and impaired exercise tolerance.

While conventional pharmaceutical treatments and revascularization procedures (such as stents or bypass surgery) slow progression, they do not regenerate dead cardiac muscle. Regenerative medicine aims to bridge this gap.

A specialized population of stem cells—Multilineage-Differentiating Stress-Enduring (MUSE) cells—has gained attention for its potential to repair ischemic heart damage.

What Are MUSE Stem Cells?

Discovered in 2010 by Dr. Mari Dezawa at Tohoku University, MUSE cells are a rare subpopulation of naturally occurring stem cells found within the connective tissue of various organs, bone marrow, and umbilical cord tissue. They are identified by the surface marker SSEA-3 (Stage-Specific Embryonic Antigen-3).

MUSE cells possess two critical characteristics that distinguish them from standard stem cell populations:

Pluripotent-Like Differentiation: Unlike typical multipotent Mesenchymal Stem Cells (MSCs), MUSE cells can differentiate into cells of all three germ layers (ectodermal, endodermal, and mesodermal), including functional cardiac muscle cells and vascular endothelial cells.

Inherent Stress Endurance & Non-Tumigenicity: Unlike embryonic stem cells (ESCs) or induced pluripotent stem cells (iPSCs), MUSE cells do not form teratomas (tumors). They thrive in harsh, hypoxic (low-oxygen) environments, making them suitable for survival within acute infarct zones.

Understanding how stem cell therapy works provides vital context for how these cellular mechanisms initiate tissue repair throughout damaged organs.

How MUSE Stem Cells Function in Ischemic Heart Disease

When administered via simple intravenous (IV) infusion, stem cells must navigate through the circulatory system and engraft into damaged tissue. A systematic review evaluating seven published studies (comprising four preclinical animal models and three preliminary human clinical investigations) highlighted key mechanisms through which MUSE cells act on ischemic cardiac tissue:

1. Selective Homing Mechanism

Damaged heart muscle releases signaling molecules, primarily Sphingosine-1-Phosphate (S1P). MUSE cells express the corresponding S1PR2 receptor on their surface, allowing them to detect this “distress signal” and migrate through the bloodstream directly to the infarct border zone.

2. Microvascular Angiogenesis and Tissue Repair

Once engrafted in the ischemic site, MUSE cells promote angiogenesis—the formation of new capillaries and micro-blood vessels. Restoring blood supply to the border zone prevents surviving cardiomyocytes from undergoing apoptosis (programmed cell death), limiting the expansion of scar tissue.

3. Improvement in Left Ventricular Ejection Fraction (LVEF)

Across preclinical and clinical studies, intravenous administration of MUSE cells correlated with a statistically significant increase in ejection fraction—the percentage of blood the left ventricle pumps out with each contraction. Research evaluating stem cell therapy for cardiovascular diseases highlights similar restorative trends across broader clinical trials.

Measure

Pre-Therapy Observation

Post-MUSE Cell Infusion Outcome

Tissue Homing

Diffuse circulation

Selective migration to S1P damage markers

Infarct Border

Expanding cellular necrosis

Preservation of border-zone cardiomyocytes

Vascular Density

Ischemic restriction

Increased microvascular endothelial density

Cardiac Function

Reduced ejection fraction

Improved LVEF & reduced scar size

Safety Profile: What Do the Studies Show?

Safety is a primary concern when introducing cell-based therapies for cardiovascular conditions. The systematic findings across published animal models and preliminary human cohorts demonstrated:

Zero Teratoma Formation: Unlike synthetic pluripotent lines, MUSE cells naturally limit their proliferation once tissue repair is underway, avoiding tumor formation.

Low Immunogenicity: MUSE cells express low levels of major histocompatibility complex (MHC) class I molecules and lack MHC class II molecules, minimizing the risk of host immune rejection.

No Arrhythmogenic Signal: Direct intramyocardial injections of certain cell types can sometimes trigger dangerous heart rhythm disturbances. Intravenous delivery of MUSE cells did not induce ventricular arrhythmias.

Observing how the body reacts to stem cell injections helps clarify why systemic tolerance is typically high when non-immunogenic cell types are introduced.

Comparing MUSE Cells and Umbilical Cord Mesenchymal Stem Cells (UC-MSCs)

While research into isolated MUSE cell formulations advances through clinical trial phases, Umbilical Cord-Derived Mesenchymal Stem Cells (UC-MSCs) remain the most widely utilized, clinically validated biologic in international regenerative medicine.

UC-MSCs also contain a natural subpopulation of SSEA-3+ MUSE cells (roughly 1% to 3% of the total MSC population). Patients often review umbilical cord tissue cell therapy to understand how these donor-derived tissues supply viable, robust cell populations.

Both therapies offer unique advantages for cardiac care:

UC-MSCs: Provide potent paracrine activity, releasing growth factors, cytokines, and vesicles. A closer look at how exosomes play into regenerative therapy reveals how these cellular messengers help modulate inflammation and prevent progressive tissue fibrosis.

MUSE Cells: Offer targeted structural differentiation directly into lineage-specific tissue at the injury site.

Understanding the unique advantages of mesenchymal stem cells in regenerative medicine underscores why MSC-based formulations continue to dominate translational research for complex tissue repair.

Clinical Status and The Road Ahead

Although preclinical data and early human safety trials are encouraging, isolated MUSE cell therapies remain investigational. Phase 2 and Phase 3 randomized controlled trials are ongoing globally to define standardized dosing protocols, optimal delivery windows post-infarction, and long-term survival metrics.

For patients exploring non-surgical strategies for advanced heart failure, learning how to deal with congestive heart failure can clarify how lifestyle changes, traditional medicine, and biological therapies intersect.

For patients currently managing chronic ischemic heart disease or recovering from a past myocardial infarction, regenerative therapies utilizing umbilical cord-derived stem cells and exosomes provide a practical non-surgical pathway to support cardiovascular health and function.

Exploring Regenerative Options with R3 Stem Cell

As a provider of regenerative therapies, R3 Stem Cell has delivered over 30,000 safe and effective stem cell procedures across international Centers of Excellence. R3’s customized treatment protocols utilize high-potency umbilical cord-derived biologics—rich in growth factors, exosomes, and regenerative cell populations—designed to support tissue repair and improve overall quality of life.

If you or a loved one are seeking non-surgical options for heart disease, chronic joint pain, or degenerative conditions:

Visit Us Online: Learn more about our clinical protocols at r3stemcell.com </a : .

Schedule a Free Consultation: Connect with an R3 patient care specialist to discuss candidacy by calling +1 (844) GET-STEM.

Contact Us